Perrigo Company plc
HealthcareNYSE:PRGO · New York Stock Exchange
+$0.09 today
Vol 2.50M · Avg 3.05M
Cash Flow
Check whether earnings turn into cash
Use operating cash flow, capital spending, free cash flow, and financing activity to see how much value is left for reinvestment or owners.
Free Cash Flow
Net Income to FCF bridge
Analysis
Analysis will appear once cash flow data is available for this period.
Cash Flow Statement
Annual data · 5 periods
| Metric | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 |
|---|---|---|---|---|---|---|---|---|
| Net Income | -$1.4B -716.2% | -$171.8M -1252.8% | -$12.7M +90.3% | -$130.9M -90.0% | -$68.9M | $487.6M | $476.4M | $465.2M |
| Depreciation & Amortization | $337.5M +3.6% | $325.9M -9.3% | $359.5M +6.2% | $338.6M +8.5% | $312.2M | $374.2M | $1.2B | $631.8M |
| Deferred Income Tax | -$50.8M -618.4% | $9.8M +109.2% | -$106.6M -111.1% | -$50.5M -637.2% | $9.4M | $1.4B | -$1.5B | $304.2M |
| Stock-Based Compensation | $0 -100.0% | $64.4M -6.4% | $68.8M | $0 -100.0% | $60.1M | $489.0M | $354.6M | -$1.6B |
| Change in Working Capital | -$101.1M -35.3% | -$74.7M -27.7% | -$58.5M -392.5% | $20.0M +106.8% | -$295.4M | $350.4M | -$1.6B | $1.5B |
| Accounts Receivables | $30.7M +376.6% | -$11.1M +80.6% | -$57.1M -57200.0% | $100.0K +100.1% | -$159.7M | $592.6M | $1.3B | $626.2M |
| Inventory | -$61.1M -546.0% | $13.7M -29.4% | $19.4M +125.3% | -$76.7M -3095.8% | -$2.4M | $1.0B | $1.2B | $1.1B |
| Accounts Payables | -$28.7M -153.0% | $54.2M +182.2% | -$65.9M -165.7% | $100.3M +1369.6% | -$7.9M | $948.2M | -$1.5B | $433.0M |
| Other Working Capital | -$42.0M +68.1% | -$131.5M -391.6% | $45.1M +1318.9% | -$3.7M +97.0% | -$125.4M | $567.4M | $1.3B | $601.0M |
| Other Non-Cash Items | $1.5B +595.3% | $209.3M +35.0% | $155.0M +19.1% | $130.1M -6.3% | $138.9M | $1.4B | -$1.5B | $300.0M |
| Operating Cash Flow | $238.5M -34.3% | $362.9M -10.5% | $405.5M +32.0% | $307.3M +96.6% | $156.3M | $7.2B | $8.9B | $10.5B |
| Capital Expenditures | -$93.4M +21.0% | -$118.3M -16.3% | -$101.7M -5.5% | -$96.4M +36.6% | -$152.1M | $664.0M | $1.4B | $697.6M |
| Acquisitions (Net) | $0 | $0 | $0 +100.0% | -$2.0B -230.9% | $1.5B | $937.0M | $1.1B | $1.3B |
| Purchases of Investments | $0 | $0 | $0 | $0 | $0 | $444.2M | $1.4B | $1.3B |
| Sales of Investments | $0 | $0 | $0 | $0 | $0 | $822.2M | $318.2M | -$1.5B |
| Other Investing Activities | $18.0M -90.9% | $197.1M +714.5% | $24.2M -73.3% | $90.5M +241.4% | -$64.0M | $616.4M | $370.0M | $1.2B |
| Investing Cash Flow | -$75.4M -195.7% | $78.8M +201.7% | -$77.5M +96.0% | -$2.0B -253.5% | $1.3B | $4.8B | $6.4B | $5.1B |
| Debt Repayment | -$34.8M +92.1% | -$437.8M -1349.7% | -$30.2M -105.2% | $583.6M +2007.2% | -$30.6M | $680.8M | $759.2M | $1.1B |
| Common Stock Issued | $0 | $0 | $0 | $0 | $0 | $778.8M | $946.8M | $812.4M |
| Common Stock Repurchased | $0 | $0 | $0 | $0 | $0 | $351.8M | -$1.6B | $1.5B |
| Dividends Paid | -$159.3M -4.5% | -$152.5M -1.9% | -$149.7M -5.1% | -$142.4M -9.9% | -$129.6M | $535.2M | $613.6M | $692.0M |
| Other Financing Activities | -$26.4M -27.5% | -$20.7M -183.6% | -$7.3M +62.8% | -$19.6M -5.9% | -$18.5M | -$1.6B | $1.3B | $1.1B |
| Financing Cash Flow | -$220.5M +63.9% | -$611.0M -226.4% | -$187.2M -144.4% | $421.6M +335.9% | -$178.7M | $12.2B | $13.9B | -$15.5B |
| Effect of Forex Changes | $30.2M +230.2% | -$23.2M -336.7% | $9.8M +128.4% | -$34.5M -121.2% | -$15.6M | $1.3B | $1.1B | $990.2M |
| Net Change in Cash | -$27.2M +85.9% | -$192.5M -227.8% | $150.6M +111.9% | -$1.3B -202.5% | $1.2B | $3.2B | $4.9B | $6.5B |
| Free Cash Flow | $145.1M -40.7% | $244.6M -19.5% | $303.8M +44.0% | $210.9M +4921.4% | $4.2M | $8.6B | -$16.8B | $11.1B |
Older periods hidden.
Sign in to unlockCompetitors
Peer companies in the same sector
Scholar Rock Holding Corporation
NASDAQ:SRRK
$5.29B
Amicus Therapeutics, Inc.
FOLD
$4.55B
LivaNova PLC
NASDAQ:LIVN
$4.36B
Heartflow, Inc. Common Stock
NASDAQ:HTFL
$2.87B
Tarsus Pharmaceuticals, Inc.
NASDAQ:TARS
$2.67B
Supernus Pharmaceuticals, Inc.
NASDAQ:SUPN
$2.58B
Surgery Partners, Inc.
NASDAQ:SGRY
$2.00B
HUTCHMED (China) Limited
NASDAQ:HCM
$1.91B
Bausch Health Companies Inc.
NYSE:BHC
$1.89B
Alphatec Holdings, Inc.
NASDAQ:ATEC
$1.27B
SEC Filings
Recent regulatory filings
No filings found.
Does PRGO generate free cash flow?
Perrigo Company plc (PRGO) generated $145.10M of free cash flow in fiscal 2025.
How much operating cash flow does PRGO produce?
Operating cash flow was $238.50M, before capital expenditures of $93.40M.
Explore More
Continue the stock analysis
Jump to another research area for this company.